Treatment of Crimean-Congo Haemorrhagic Fever by Favipiravir in a Patient with Novel Coronavirus Co-Infection
  • Ahmet Cumhur Dülger
    Department of Gastroenterology, Giresun State Hospital Affiliated to Giresun University,Giresun, Turkey
  • Mustafa Yakarişik
    Department of Internal Medicine, Giresun State Hospital Affiliated to Giresun University,Giresun, Turkey
  • Yusuf Emre Uzun
    Department of Internal Medicine, Dereli State Hospital, Giresun, Turkey
  • Ahmet Melih Şahin
    Department of Infectious Disease, Giresun State Hospital Affiliated to Giresun University, Giresun, Turkey

Keywords

Crimean-Congo haemorrhagic fever, COVID-19, favipiravir

Abstract

Introduction: Crimean-Congo haemorrhagic fever (CCHF) is a lethal zoonotic disease caused by an RNA virus that is a member of the Nairovirus genus in the Bunyaviridae family from the arbovirus group. CCHF is transmitted by Hyalomma ticks through direct contact with the blood and other bodily fluids of patients or infected animals.

Case description: A 65-year-old man was admitted to the emergency unit with dry cough, myalgia and fever. He was treated with favipiravir. He had disseminated intravascular coagulopathy with thrombocytopenia in the setting of COVID-19 infection. He tested positive for both COVID-19 and CCHF. By the end of the fifth day of treatment, his laboratory parameters and clinical symptoms had normalized.

Conclusion: Favipiravir is currently on the market for treating COVID-19 infection worldwide. It has also been used to treat CCHF in laboratory animals. To the best of our knowledge this is the first report of CCHF successfully treated with favipiravir, which could be a key drug for treating human CCHF.

VIEW THE ENTIRE ARTICLE

References

  • Shayan S, Bokaean M, Shahrivar MR, Chinikar S. Crimean-Congo hemorrhagic fever. Lab Med 2015;46(3):180–189.
  • Messina JP, Pigott DM, Golding N, Duda KA, Brownstein JS, Weiss DJ, et al. The global distribution of Crimean-Congo hemorrhagic fever. Trans R Soc Trop Med Hyg 2015;109(8):503–513.
  • Taisheng L. Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical College Hospital (V2.0). Emerg Microbes Infect 2020;9(1):582–585.
  • Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 2017;93(7):449–463.
  • Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antivir Res 2018;153:85–94.
  • Acter T, Uddin N, Das J, Akhter A, Choudhury TR, Kim S. Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: a global health emergency. Sci Total Environ 2020;730:138996.
  • Hawman DW, Feldmann H. Recent advances in understanding Crimean-Congo hemorrhagic fever virus. F1000Res 2018;7:F1000 Faculty Rev-1715.
  • Sas MA, Vina-Rodriguez A, Mertens M, Eiden M, Emmerich P, Chaintoutis SC, et al. A one-step multiplex real-time RT-PCR for the universal detection of all currently known CCHFV genotypes. J Virol Methods 2018;255:38–43.
  • Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun 2020;87:59–73.
  • Oestereich L, Rieger T, Neumann M, Bernreuther C, Lehmann M, Krasemann S, et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis 2014;8(5):e2804.
  • Hawman DW, Haddock E, Meade-White K, Williamson B, Hanley PW, Rosenke K, et al. Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Antivir Res 2018;157:18–26.

    • Views: 979
    HTML downloads: 69
    PDF downloads: 537

    Published: 2020-12-17
    Issue: 2020: Vol 7 No 12 (view)

    How to cite:
    1.
    Dülger AC, Yakarişik M, Uzun YE, Şahin AM. Treatment of Crimean-Congo Haemorrhagic Fever by Favipiravir in a Patient with Novel Coronavirus Co-Infection. EJCRIM 2020;7 doi:10.12890/2020_002042.

    Similar Articles

    You may also start an advanced similarity search for this article.